4//SEC Filing
Sullivan Lara 4
Accession 0001209191-23-049366
CIK 0001782223other
Filed
Sep 12, 8:00 PM ET
Accepted
Sep 13, 8:16 PM ET
Size
10.4 KB
Accession
0001209191-23-049366
Insider Transaction Report
Form 4
Sullivan Lara
DirectorPresident ,CEO & CMO
Transactions
- Sale
Common Stock
2023-09-13$2.27/sh−3,000$6,816→ 2,597,265 total - Sale
Common Stock
2023-09-11$2.27/sh−20,000$45,414→ 2,605,182 total - Sale
Common Stock
2023-09-12$2.25/sh−4,917$11,071→ 2,600,265 total - Tax Payment
Common Stock
2023-09-13$2.13/sh−184,742$393,500→ 2,412,523 total
Footnotes (5)
- [F1]Reflects sales of common stock executed in multiple transactions. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected within the ranges set forth in footnotes 2 through 4 of this Form 4.
- [F2]The transaction was executed in multiple trades in prices ranging from $2.13 to $2.36.
- [F3]The transaction was executed in multiple trades in prices ranging from $2.21 to $2.30.
- [F4]The transaction was executed in multiple trades in prices ranging from $2.25 to $2.34.
- [F5]Represents shares withheld to cover taxes due upon the vesting of certain restricted stock units.
Documents
Issuer
Pyxis Oncology, Inc.
CIK 0001782223
Entity typeother
Related Parties
1- filerCIK 0001769457
Filing Metadata
- Form type
- 4
- Filed
- Sep 12, 8:00 PM ET
- Accepted
- Sep 13, 8:16 PM ET
- Size
- 10.4 KB